Wall Street Analysts Believe Veracyte (VCYT) Could Rally 35.05%: Here's is How to Trade
The mean of analysts' price targets for Veracyte (VCYT) points to a 35.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Veracyte Stock Surges 45.6% in a Year: What's Driving the Rally?
Strength in VCYT's Afirma and Decipher tests continues to draw investors' attention.
Solid Growth, Soft Outlook: Why I'm Holding On Veracyte
Veracyte, Inc. shows strong revenue growth and market share in genomic diagnostics, particularly with its Decipher and Afirma tests, but faces significant near-term challenges. 2024 ended positively with 23% revenue growth and strong cash flow, yet 2025 will be critical for transitioning to a stable, profit-generating leader. Regulatory uncertainties, Afirma's growth deceleration, and potential financial issues from selling the French subsidiary pose risks to Veracyte's near-term performance.
Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.
Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript
Veracyte, Inc. (NASDAQ:VCYT ) Q4 2024 Earnings Conference Call February 24, 2025 4:30 PM ET Company Participants Shayla Gorman - Senior Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Research, LLC Mason Carrico - Stephens Inc. Puneet Souda - Leerink Partners Maggie Boeye - William Blair & Company Lu Li - UBS Group AG Corey Rosenbaum - Scotiabank Subbu Nambi - Guggenheim Securities, LLC Yuko Oku - Morgan Stanley Joseph Conway - Needham & Company, LLC Prashant Kota - Goldman Sachs Operator Good day, and thank you for standing by. Welcome to the Veracyte Fourth Quarter and Full Year 2024 Financial Results webcast.
Veracyte (VCYT) Q4 Earnings and Revenues Beat Estimates
Veracyte (VCYT) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.29 per share. This compares to loss of $0.04 per share a year ago.
Is Veracyte Stock a Good Addition to Your Portfolio Right Now?
VCYT stays on investors radar due to the strong performance of the Afirma and Decipher franchises.
Veracyte Gains 44% in a Year: What's Driving the Stock?
VCYT is gaining shares due to the strength of its Afirma and Decipher tests.
Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now
Veracyte's progress with key drivers and the strength in its diagnostics tests bring optimism to investors.
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Veracyte Q3 Earnings Beat Estimates, 2024 Guidance Raised
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.
Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript
Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript
